Bill
S 3203
Overview: S 3203, "Preserves access to affordable drugs", was referred to the Health committee on November 19, 2025.Purpose and Intent: The main goal of this bill is to ensure cont
Overview: S 3203, "Preserves access to affordable drugs", was referred to the Health committee on November 19, 2025.
Purpose and Intent: The main goal of this bill is to ensure continued access to affordable prescription drugs for consumers. It aims to address concerns about rising drug prices and potential barriers to accessing essential medications.
Key Provisions:
- Prohibits pharmaceutical companies from engaging in "pay-for-delay" agreements that delay the introduction of generic drugs
- Requires drug manufacturers to provide the government with advance notice of planned price increases above a certain threshold
- Empowers the Federal Trade Commission to take enforcement action against unfair drug pricing practices
Affected Parties and Impacts: This bill would primarily impact consumers who rely on prescription drugs, as well as pharmaceutical companies and generic drug manufacturers. It is intended to help keep drug prices affordable and accessible, especially for vulnerable populations.
Procedural and Timeline Considerations: The bill has been referred to the Senate Health committee and is currently awaiting further legislative action.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
